Evidence map›Paper›PMID 32949451›Full record

ArticleInternational journal of laboratory hematology2021

The Sysmex XN-L (XN-350) hematology analyzer offers a compact solution for laboratories in niche diagnostics.

Tania A Khartabil, Magda M de Frankrijker, Yolanda B de Rijke, Henk Russcher

Abstract read
In one paragraph

Article in International journal of laboratory hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tania A KhartabilDepartment of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0002-7083-1710
Magda M de FrankrijkerDepartment of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Yolanda B de RijkeDepartment of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-7759-4968
Henk RusscherDepartment of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-7289-7572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn 2015, Sysmex launched a new series of hematology analyzers (XN-L Series) designed to fulfill the needs of niche laboratories in areas such as pediatrics, dialysis, neurology, and oncology while providing a compact solution. In this study, we evaluate the whole blood and body fluid modes of one of these analyzers, the XN-350.

methodsA total of 300 residual EDTA samples were measured on the XN-350 in whole blood mode and the XN-1000 to evaluate method comparison, flagging sensitivity, repeatability, reproducibility, linearity, carryover, and stability. In addition, 191 samples were obtained and processed in body fluid mode which included, cerebrospinal fluid (CSF), continuous ambulatory peritoneal dialysis (CAPD), ascites, synovial, and pleural fluid to perform method comparison, repeatability, reproducibility, linearity, limit of quantitation, and carryover studies.

resultsStrong agreement was shown between the XN-350 and XN-1000 for both whole blood and body fluid modes in results and flagging. Linearity results in both modes on the XN-350 showed a high R

conclusionThe performance of the XN-350 is comparable to the XN-1000 in both whole blood and body fluid modes, making it a reliable alternative to larger analyzers for smaller, niche laboratories.

Indexed as

Automation, LaboratoryHematologic TestsHumansbody fluid analysisSysmex XN-1000Sysmex XN-350Sysmex XN-L Serieswhole blood analysis

Identifiers

PMID32949451
PMCPMC7891428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.